Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.48 |
| ▸ | RAB9A | P51151 | 11/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | UTRN | P46939 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084921 | 0.85 | CETP (0.49) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6084890 | 0.82 | RAB9A (0.55) | NPC1RAB9APOLBCETPPKM | |
| SCHEMBL6085938 | 0.82 | CETP (0.50) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6085768 | 0.81 | CETP (0.49) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6085596 | 0.80 | CETP (0.48) | RAB9APOLBMEN1KMT2ACETP | |
| SCHEMBL6087087 | 0.79 | CETP (0.45) | NPC1RAB9APOLBCETPSMN1; SMN2 | |
| SCHEMBL6085503 | 0.78 | TP53 (0.46) | CETPCYP1A2AHRUTRNHDAC6 | |
| SCHEMBL6085871 | 0.77 | CETP (0.49) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6085790 | 0.77 | TP53 (0.40) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6084877 | 0.75 | RAB9A (0.52) | NPC1RAB9APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | NPC1 4031/4885RAB9A 2584/4885POLB 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.